Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

In the last decade, better understanding of the role of epidermal growth factor receptor in the pathogenesis and progression of non-small cell lung cancer has led to a revolution in the work-up of these neoplasms. Tyrosine kinase inhibitors, such as erlotinib and gefitinib, have been approved for th...

Descripción completa

Detalles Bibliográficos
Autores principales: Berardi, Rossana, Santoni, Matteo, Morgese, Francesca, Ballatore, Zelmira, Savini, Agnese, Onofri, Azzurra, Mazzanti, Paola, Pistelli, Mirco, Pierantoni, Chiara, De Lisa, Mariagrazia, Caramanti, Miriam, Pagliaretta, Silvia, Pellei, Chiara, Cascinu, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665567/
https://www.ncbi.nlm.nih.gov/pubmed/23723712
http://dx.doi.org/10.2147/OTT.S28155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3665567/
https://www.ncbi.nlm.nih.gov/pubmed/23723712
http://dx.doi.org/10.2147/OTT.S28155

Ejemplares similares